https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/spinraza-first-treatment-spinal-muscular-atrophy-receive-fda-approval/
Spinraza: the first treatment for spinal muscular atrophy to receive FDA approval
30 Mar 2017, 11:28 a.m.
At the end of 2016, the American Food and Drug Administration (FDA) granted approval for the use of Spinraza (nusinsersen) for the treatment of spinal muscular atrophy (SMA) in paediatric and adult patients. This is unprecedented for the SMA community witnessing the first approved drug for this disease.
The FDA approval was based on positive results from multiple clinical studies in more than 170 patients. GOSH was the highest UK recruiter for the first study, ENDEAR, a Phase 3, controlled study evaluating Spinraza in infantile-onset, which took place in the BRC-supported Somers Clinical Research Facility.
The interim analysis of the data from ENDEAR, (previously reported in the December BRC newsletter) was considered throughout the approval process. In particular, patients with infantile-onset SMA recruited to the ENDEAR study and treated with Spinraza, achieved and sustained clinically meaningful improvement in motor function compared to untreated study participants. Furthermore, a greater percentage of patients on Spinraza survived compared to untreated patients. In open-label studies, some patients also achieved unexpected milestones such as ability to sit unassisted, stand or walk.
Duchenne Muscular Dystrophy gene therapy trial highlights complexity of disease
The first large-scale trial of gene therapy for the debilitating neuromuscular disease, Duchenne Muscular Dystrophy (DMD) has been carried out
New hope to prevent blindness in children with rare genetic disease
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).
New clinical trial at GOSH gives hope to children with aggressive blood cancer
Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)
Important step forward in stem cell therapy for rare bowel disease
A new study led by researchers at UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) and the Centre for Stem Cell Biology, University of Sheffield, has demonstrated the potential of stem cell therapy to treat those with Hirschsprung disease.